Domestic price of Erdafitinib

Erdafitinib (Erdafitinib) was approved in the United States in 2019 for the treatment of patients with locally advanced, unresectable, or metastatic urothelial carcinoma harboring FGF receptor 3 or 2 mutations. Erdafitinib is currently being evaluated in several other cancers with FGF receptor mutations, including cholangiocarcinoma, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, prostate cancer, and lymphoma.

Erdafitinib is available in 3, 4 and 5 mg tablets under the brand name Balversa. The recommended dose is 8 mg once daily, which can be increased to 9 mg daily. Adverse effects, including hyperphosphatemia, stomatitis, diarrhea, dry mouth, decreased appetite, dysgeusia, dry skin, alopecia, constipation, anemia, thrombocytopenia, and elevated serum creatinine, amylase, lipase, alkaline phosphatase, and aminotransferases, occur in nearly all patients treated with erdafitinib. Uncommon but potentially serious side effects include retinal detachment, cataracts, severe hyperphosphatemia, and embryo-fetal toxicity.

The original drug of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong, SpecificationsThe price of 4mg*14 tablets per box may be more than 20,000 yuan (the price may fluctuate due to the exchange rate), which is relatively expensive. Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).